Skip to main content
. 2021 Nov 15;12(11):1856–1874. doi: 10.4239/wjd.v12.i11.1856

Table 2.

Interventional and observational studies on glycemic control in type 2 diabetes mellitus patients and coronary artery calcification outcomes

Ref.
Year
HbA1c (%), mean ± SD
Type of study
Intervention
Sample size
Main findings
Razavi et al[43] 2021 Fasting glucose > 126 mg/dL Multiethnic cohort Two CAC scans with a 10-yr interval 574 More than 40% of adults with MetS or T2DM and baseline CAC = 0 had long-term absence of CAC
Schindler et al[34] 2009 9.8 ± 2.7 Prospective Glyburide 10-20 mg/d ± metformin 500-1000 mg/d; Observation for 14 ± 2 mo 39 Lower progression of cIMT and CAC with glucose-lowering treatment
Won et al[38] 2018 7.5 ± 1.2 and 6.4 ± 0.9 Retrospective, single-ethnicity, multicenter observational Data on the impact of optimal glycemic control on CAC progression 1637 Attenuation of CAC progression, especially if CAC > 400
Funck et al[41] 2017 6.5 ± 0.7 Prospective cohort Observational, 5-yr follow-up 106 CAC progression in DM compared to healthy. Independently associated with PWV
Malik et al[42] 2017 HbA1c measurements were not available at baseline Prospective cohort Observational 6814 Baseline CAC values most important progression determinant

CAC: Coronary artery calcification; cIMT: Carotid intima media thickness; DM: Diabetes mellitus; MetS: Metabolic syndrome; PWV: Pulse wave velocity; SD: Standard deviation; T2DM: Type 2 diabetes mellitus.